Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,257 total articles

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics announced that the U.S. FDA has granted their appeal following the Formal Dispute Resolution process regarding their Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for treating neovascular age-related macular degeneration (nAMD). The FDA recognizes substantial evidence of effectiveness from clinical tri…

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting

Tonix Pharmaceuticals disclosed results from a comprehensive retrospective U.S. real-world claims analysis involving over 261,000 fibromyalgia patients, emphasizing the high comorbidity burden and extensive healthcare resource utilization associated with the condition. The company recently commercialized TONMYA®, a novel non-opioid analgesic approv…

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy

Jade Biosciences announced the dosing of the first participant in its Phase 2 JUNIPER clinical trial evaluating JADE101, a monoclonal antibody targeting APRIL, in patients with immunoglobulin A nephropathy (IgAN). JADE101 aims to reduce pathogenic IgA production, offering a potentially effective and convenient treatment for this chronic autoimmune …

Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

Corbus Pharmaceuticals announced updated positive clinical results from its Phase 1/2 trial of CRB-701 (SYS6002), a next-generation Nectin-4 targeted antibody drug conjugate, showing robust efficacy in second-line oropharyngeal squamous cell carcinoma and cervical cancer. The treatment demonstrated confirmed objective response rates of 42.9% in OPS…

Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

Axsome Therapeutics announced presentations of new clinical data for AUVELITY, its treatment for major depressive disorder, at the American Society of Clinical Psychopharmacology 2026 Annual Meeting. The data focus on efficacy in patients with anxious distress and real-world clinical outcomes, demonstrating the drug's potential benefits and expandi…

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026

Climb Bio, a clinical-stage biotech company, announced it will present new clinical data for its immunotherapy candidates CLYM116 and budoprutug at the European Renal Association Congress 2026. CLYM116 targets APRIL to treat IgA nephropathy, with initial Phase 1 safety data to be shown, while budoprutug, an anti-CD19 antibody, is in Phase 2 trials …

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

Cullinan Therapeutics announced an in-person Immunology Day event to showcase promising initial and updated clinical data from over 30 patients in systemic lupus erythematosus and rheumatoid arthritis studies using CLN-978 and Velinotamig, both T cell engager therapies. The company highlighted progress in multi-dose cohorts and shared plans for adv…

AutoZone 3rd Quarter Total Company Same Store Sales Increase 3.9%; Domestic Same Store Sales Increase 4.1%; EPS of $38.07

AutoZone 3rd Quarter Total Company Same Store Sales Increase 3.9%; Domestic Same Store Sales Increase 4.1%; EPS of $38.07

AutoZone, Inc. reported an 8.4% increase in net sales to $4.8 billion for the third quarter ended May 9, 2026. Total company same store sales increased 3.9% (constant currency), driven by a 4.1% domestic same store sales growth. Operating profit rose 6.6% to $923.8 million, with diluted EPS increasing to $38.07 compared to $35.36 last year. The com…

CSW Industrials Reports Robust Fiscal 2026 Fourth Quarter with Record Quarterly and Full Year Results; Contractor Solutions Segment Returns to Positive Organic Growth in Fourth Quarter

CSW Industrials Reports Robust Fiscal 2026 Fourth Quarter with Record Quarterly and Full Year Results; Contractor Solutions Segment Returns to Positive Organic Growth in Fourth Quarter

CSW Industrials announced record revenue and adjusted EBITDA for fiscal 2026, driven primarily by strategic acquisitions and solid organic growth in the Contractor Solutions and Specialized Reliability Solutions segments. Despite some reported EPS decline due to non-cash impairments and higher interest expenses, adjusted EPS increased by 6.9% year-…

Editas Medicine Announces Proposed Public Offering

Editas Medicine Announces Proposed Public Offering

Editas Medicine, a gene editing company listed on Nasdaq, announced the commencement of an underwritten public offering of its common stock and accompanying warrants. The offering is subject to market conditions and aims to raise capital to support its pipeline of CRISPR-based transformative medicines. Cantor and Wells Fargo Securities are managing…

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

Kura Oncology announced encouraging first-in-human data from its FIT-001 trial evaluating darlifarnib plus adagrasib in heavily pretreated patients with KRAS G12C-mutated advanced solid tumors, including pancreatic, lung, and colorectal cancers. Tumor shrinkage was observed in 77% of evaluable patients with objective response rates of 67% in pancre…

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Editas Medicine announced positive preclinical data demonstrating that a single dose of its gene-editing candidate, EDIT-401, achieved approximately 90% reductions in LDL cholesterol, Lp(a), and ApoB in non-human primates. These findings support EDIT-401 as a potentially best-in-class in vivo gene editing therapy for hyperlipidemia and cardiovascul…

BGIN BLOCKCHAIN LIMITED Launches ASIC Chip Customization Solutions Business and Completes Inaugural Customer Delivery

BGIN BLOCKCHAIN LIMITED Launches ASIC Chip Customization Solutions Business and Completes Inaugural Customer Delivery

BGIN Blockchain Limited announced the launch of its ASIC Chip Customization Solutions business, leveraging its expertise in ASIC chip design and mining hardware engineering to serve third-party customers. The company completed its inaugural delivery of 3,000 customized mining machines to a Proof-of-Work protocol project, marking its entry into offe…

Auddia Reports Strong Artist and Industry Response to Discovr Radio’s Toronto Debut at Departure Festival + Conference, Identifies City as Key Growth Hub

Auddia Reports Strong Artist and Industry Response to Discovr Radio’s Toronto Debut at Departure Festival + Conference, Identifies City as Key Growth Hub

Auddia Inc. reported a highly successful debut of its AI-driven artist discovery platform, Discovr Radio, at the Departure Festival + Conference in Toronto. The event drew over 65 demo submissions and significant attendance, demonstrating strong demand for AI-powered, data-driven music promotion in the Canadian market. Toronto is identified as a st…

New TransUnion Study Challenges Credit Myths About Canadian Gig Workers

New TransUnion Study Challenges Credit Myths About Canadian Gig Workers

TransUnion's new study challenges credit myths about Canadian gig workers, highlighting their responsible credit behavior and significant role in household income. The report shows gig workers have credit profiles similar to the general population but face obstacles in credit applications, underscoring a need for lenders to adapt credit assessment …

Emira 420 Sport: the lightest and most powerful Emira yet

Emira 420 Sport: the lightest and most powerful Emira yet

Lotus Technology Inc. announced the launch of the Emira 420 Sport, the most powerful and lightest version of the Emira sports car to date. Featuring a 2.0-litre turbocharged engine with 420PS, advanced lightweight materials, enhanced aerodynamics, and improved handling, the new model aims to deliver superior performance both on road and track. The …

The Resilient North: Equifax Canada Data Shows Consumers Leaning on Financial Discipline to Offset Macroeconomic Conditions

The Resilient North: Equifax Canada Data Shows Consumers Leaning on Financial Discipline to Offset Macroeconomic Conditions

Equifax Canada's Q1 2026 Market Pulse report shows Canadian consumers exercising greater financial discipline with reduced non-mortgage debt and improved credit card repayments. However, insolvency levels have risen to their highest since 2009, driven by mortgage-related financial strain, especially in high-cost markets like Ontario and British Col…

SCHMID Group N.V. Announces Various Share Issuances to Off-set Liabilities, to Directors & Officers and Key Employees and for Convertible Notes Conversions

SCHMID Group N.V. Announces Various Share Issuances to Off-set Liabilities, to Directors & Officers and Key Employees and for Convertible Notes Conversions

SCHMID Group N.V. has issued approximately 5.96 million new shares to offset EUR 30.75 million in liabilities to directors and key shareholders, compensate board members and key employees with shares instead of cash bonuses, and convert USD 4 million in convertible notes. These actions aim to reduce financial liabilities, preserve cash, and enhance…

PONY AI Inc. Reports First Quarter 2026 Financial Results with Continued Growth in Robotaxi Revenues and Expanding Fleet Deployment

PONY AI Inc. Reports First Quarter 2026 Financial Results with Continued Growth in Robotaxi Revenues and Expanding Fleet Deployment

Pony AI Inc. reported a significant increase in first quarter 2026 revenues, driven primarily by a 395.4% year-over-year growth in Robotaxi services and expansions in its autonomous vehicle fleet. The company raised its 2026 targets for Robotaxi revenues and fleet size, expanding its operational footprint domestically in China and internationally i…